COVID-19 / SARS CoV-2 Antibodies EQA
| Accreditation Status: | UKAS Schedule of Accreditation | ||||||
| Date Scheme started: | 2020 | ||||||
| Clinical Applicability: | Detection of antibodies to SARS-CoV-2 / COVID-19 confirming previous infection | ||||||
| Analytes: | Antibodies to SARS-CoV-2 as IgG, Total Ig (SER/059) | ||||||
| Units for Reporting: |
Qualitative and quantitative responses, method dependent |
||||||
| Samples Distributed: | Liquid format. Normal and pathological human serum | ||||||
| Number of Distributions per year: | 6 | ||||||
| Number of Samples per Distribution: | 2 | ||||||
| Frequency of Distributions: | Every two months as outlined in the Distribution Schedule | ||||||
| Schedule of Analysis: | Data entry is via the web for the submission of results. Data analysis commences 21 days after sample dispatch. Late returns are accepted and will contribute to the laboratory's cumulative performance statistics. | ||||||
| Data Analysis: |
Qualitative responses are recorded for antibodies to SARS-CoV-2 as IgG and as Total Ig and assessed in relation to the designated response. Reports show method or kit related statistics in terms of Group Laboratory Trimmed Mean (GLTM) with truncation at 2SD, SD, and CV%. Reports also show method and manufacturer specific statistics. Chosen Coefficient of Variation for quantitative results is 20% |
||||||
| Performance Scoring: | MI Scoring | ||||||
| Criteria of Performance: |
Laboratory performance for the qualitative element of the Scheme is assessed over a running analytical window of 12 Distributions (12 months) The categories of performance are:
|
||||||
| Persistent Poor Performance: |
Defined as being in the Poor Performance category for two or more successive Distributions |